Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140
about
CCR5 monoclonal antibodies for HIV-1 therapyHumanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infectionMonoclonal CCR5 antibody for treatment of people with HIV infectionTAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humansPotent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1Molecular strategies to inhibit HIV-1 replicationNovel approaches to inhibit HIV entryHIV entry inhibitors: mechanisms of action and resistance pathwaysMicrobicides and other topical agents in the prevention of HIV and sexually transmitted infections.Closing the door to human immunodeficiency virus.Identification of a linear peptide recognized by monoclonal antibody 2D7 capable of generating CCR5-specific antibodies with human immunodeficiency virus-neutralizing activity.Peptide mimotopes selected with HIV-1-blocking monoclonal antibodies against CCR5 represent motifs specific for HIV-1 entry.The Membrane-Proximal Region of C-C Chemokine Receptor Type 5 Participates in the Infection of HIV-1.Induction of murine mucosal CCR5-reactive antibodies as an anti-human immunodeficiency virus strategyAnti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody.Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors.Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist.Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults.Rational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36.CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection.Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity.Clinical development of monoclonal antibody-based drugs in HIV and HCV diseasesIn vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor.New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infectionHIV entry inhibitors and their potential in HIV therapyConsiderations and development of topical microbicides to inhibit the sexual transmission of HIV.The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C.The isolation of novel phage display-derived human recombinant antibodies against CCR5, the major co-receptor of HIVRedox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirionsNatural anti-CCR5 antibodies in HIV-infection and -exposurePreventing sexual transmission of HSV and HIV: the challenge for active and passive immunization of mucosal surfaces.Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching.CCR5: From Natural Resistance to a New Anti-HIV Strategy.Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5).Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542.Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropismNeutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas.HIV-1 entry inhibitors: closing the front door.The second extracellular loop of CCR5 contains the dominant epitopes for highly potent anti-human immunodeficiency virus monoclonal antibodies.HIV entry and fusion inhibitors.
P2860
Q22242739-CFDFCA22-E2A7-4EFF-8DBD-C2324884F179Q24194805-E455DB7A-18F4-4E20-96F2-2432AFCAB3ADQ24235689-CC2B4F1A-30A2-4AFC-9900-C84A1A98DC9DQ24537285-3F8340D5-0DF1-4395-AA9C-D1824623B6A1Q24673555-A7C77319-789C-4748-A65A-1937CB5D6C11Q24799813-34C66435-DC24-4CF6-9977-BFEF79A341D9Q27013957-742945DB-0474-4ADF-A225-E197417C0220Q28296162-8FB376A1-C94F-4DFE-A50A-BB68B7DE0CD8Q30359545-BF0F3367-F9A0-4DFE-B1FA-C5AE0AA8B7D3Q30428089-8E748DF4-D8E7-48B8-8376-DC51D5602750Q33214992-03145A88-8A80-46D7-BE74-6F1C6AEB9C40Q33289730-8D8470EB-E166-436A-86D0-599606335259Q33595068-FF1813C8-A011-4208-A11C-63C242005340Q33788768-36EF3D5C-A03A-4F46-A33C-957B506E6F13Q33798442-A366FA0D-8F0B-45AD-BA66-4A73BFF1DFDCQ33843345-BD5BBBFD-DED8-4765-A621-688B07B4699EQ33938250-12849931-1583-4160-89B1-03D522DDC2BFQ34150882-D615CFEE-E807-434C-9E03-5B736CCAF4A7Q34174815-284DD8EE-399C-4612-84AC-55AF4B43B250Q34473072-BD8E2ACC-6412-4596-AF0F-BDD165C68E24Q34531219-DD62D29C-897A-44A7-AEC9-1E60D10B069BQ34536782-20F62D70-7F67-4EDE-81F6-0063E17F8A94Q34536817-0AFCFB95-C0B7-467B-89F7-72207FCF7255Q34568280-15B89F6E-DFA0-482E-9E7D-5AF9C3B2E98AQ34595921-29A11307-3D56-4A5B-AA11-2739D137E04EQ34768558-E6620A20-AC00-464A-810D-B8D20A973B9DQ34781878-2383B79A-4619-46DB-949C-87785F00BD06Q34939533-8E9783A8-920F-4E81-90C3-E47A21B8B468Q34977075-C4861F7F-DD3D-4FAA-87ED-9F5BAD2597ECQ35018133-34086D5B-FA27-4876-B728-9D79FE13709DQ35042478-EB9582BD-3AD7-4AF7-B82D-E49FEAA6C822Q35122466-473007BA-CC56-4350-A342-921E02311F2FQ35260605-2FD2235D-C1EE-4F90-95FC-0E5A069FD42BQ35312348-15809F9E-645C-400A-807D-251BCCB9B016Q35547693-E47C1FA0-001E-4714-9404-31A24BAE3F68Q35635933-20B8423C-C536-4F30-9B7E-36BA4F09FDFFQ35677620-4C4D0281-6CAD-402A-A0FF-A00478CC02CEQ35753350-EB34D005-956C-4832-86CB-0E46BA884B4AQ35758790-39C4566A-E07E-4CD5-88B6-8CF07876F54BQ35779267-08511AF6-3926-4FBD-A1AA-7492DCFB38B9
P2860
Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Potent, broad-spectrum inhibit ...... R5 monoclonal antibody PRO 140
@ast
Potent, broad-spectrum inhibit ...... R5 monoclonal antibody PRO 140
@en
Potent, broad-spectrum inhibit ...... R5 monoclonal antibody PRO 140
@nl
type
label
Potent, broad-spectrum inhibit ...... R5 monoclonal antibody PRO 140
@ast
Potent, broad-spectrum inhibit ...... R5 monoclonal antibody PRO 140
@en
Potent, broad-spectrum inhibit ...... R5 monoclonal antibody PRO 140
@nl
prefLabel
Potent, broad-spectrum inhibit ...... R5 monoclonal antibody PRO 140
@ast
Potent, broad-spectrum inhibit ...... R5 monoclonal antibody PRO 140
@en
Potent, broad-spectrum inhibit ...... R5 monoclonal antibody PRO 140
@nl
P2093
P2860
P1433
P1476
Potent, broad-spectrum inhibit ...... R5 monoclonal antibody PRO 140
@en
P2093
K A Nagashima
P J Maddon
T Cilliers
P2860
P304
P356
10.1128/JVI.75.2.579-588.2001
P407
P577
2001-01-01T00:00:00Z